Survival Model Established by Combined Serum Tumor Markers in Predicating the Effect of Erlotinib on Patients with Recurrent Non-small Cell Lung Cancer
Objective: To investigate the relationship of serum pulmonary surfactant-associated pretein (SP-D), transforming growth factor-α (TGF-α), matrix metalloproteinases-9 (MMP-9), tissue polypeptide specific antigen (TPS) and lung adenocarcinoma-related antigen (KL-6) with the effect and survival of trea...
Main Authors: | Lan Shao, Wei Hong, Yiping Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Third Party Medicine International Publishing Group Co. Limited
2013-12-01
|
Series: | Journal of International Translational Medicine |
Subjects: | |
Online Access: | http://www.jitm.hk/EN/abstract/abstract89.shtml |
Similar Items
-
Joint Serum Tumor Markers Serve as survival predictive model of Erlotinib in the treatment of recurrent Non-small Cell Lung Cancer
by: Lan SHAO, et al.
Published: (2014-05-01) -
Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease
by: Şenay Yılmaz, et al.
Published: (2017-04-01) -
Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-05-01) -
Effect of application of markers and immune function of patients with tumor of erlotinib combined with Addie injection in non-small cell lung cancer
by: Feng Wen, et al.
Published: (2018-09-01) -
Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)